NCT07099118View on ClinicalTrials.gov

A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

August 14, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

March 6, 2027

Conditions
Non - Alcoholic Steatohepatitis
Interventions
DRUG

HEC169584 capsule

Each dose of HEC83518 will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.

DRUG

placebo

The placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.

Trial Locations (1)

Unknown

No. 49, Huayuan North Road, Haidian District, Beijing Municipality, Beijing

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY